In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 9, 2006, Pages 3011-3018

  Hasenoehrl, Andreja ^a   Galić, Tatjana ^a   Ergović, Gabrijela ^a   Maršić, Nataša ^a   Skerlev, Mihael ^b   Mittendorf, Joachim ^c   Geschke, Ulrich ^c   Schmidt, Axel ^d   Schoenfeld, Wolfgang ^a,e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c BAYER AG   (Germany)

^d BAYER PHARMA AG   (Germany)

^e Eucodis GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 METHYLENECYCLOPENTANECARBOXYLIC ACID; AMINO ACID; AMPHOTERICIN B; ANTIFUNGAL AGENT; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; ICOFUNGIPEN; ISOLEUCINE; ISOLEUCINE TRANSFER RNA LIGASE; LEUCINE; MICONAZOLE; NYSTATIN; UNCLASSIFIED DRUG; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOASSAY; CANDIDA ALBICANS; CANDIDIASIS; COLONY FORMING UNIT; COMPETITIVE INHIBITION; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG UPTAKE; ENZYME INHIBITION; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MALE; MICRODILUTION ASSAY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; REPRODUCIBILITY;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CYCLOLEUCINE; DRUG INTERACTIONS; HYDROGEN-ION CONCENTRATION; ISOLEUCINE; MALE; MICE; MICROBIAL SENSITIVITY TESTS; RATS; RATS, SPRAGUE-DAWLEY; TEMPERATURE;

EID: 33748695567     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00254-06     Document Type: Article

References (32)

1. Asai, K., N. Tsuchimori, K. Okonogi, J. R. Perfect, O. Gotoh, and Y. Yoshida. 1999. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob. Agents Chemother. 43:1163-1169.
2. Brockmeyer, N. H., M. Ruhnke, K. Oreskovic, and J. Peterson. 2004. A phase II study of icofungipen (PLD-118) in the treatment of oropharyngeal candidiasis (OPC) in HIV-positive patients, p. 418. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C., 30 October to 2 November 2004.
3. Cartledge, J. D., J. Midgley, and B. G. Gazzard. 1997. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. AIDS 11:1839-1844.
4. Chapin, K. C., and P. R. Murray. 1999. Media, p. 1687-1707. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
5. Dismukes, W. E. 2000. Introduction to antifungal drugs. Clin. Infect. Dis. 30:653-657.
6. Ernst, E. J. 2001. Investigational antifungal agents. Pharmacotherapy 21:165S-174S.
7. Georgopapadaku, N. H. 1998. Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. 1:547-557.
8. Hossain, M., and M. Ghannoum. 2000. New investigational antifungal agents for treating invasive fungal infections. Expert Opin. Investig. Drugs 9:1797-1813.
9. Iwamoto, T., E. Tsujii, M. Ezaki, A. Fujie, S. Hashimoto, M. Okuhara, M. Kohsaka, and H. Imanaka. 1990. FR109615, a new antifungal antibiotic from Streptomyces setonii. Taxonomy, fermentation, isolation, physico-chemical properties and biological activity. J. Antibiot. 43:1-7.
10. Johnson, M. D., and J. R. Perfect. 2003. Caspofungin: First approved agent in a new class of antifungals. Expert Opin. Pharmacother. 4:807-823.
11. Klepser, M. E., E. J. Ernst, R. E. Lewis, M. E. Ernst, and M. A. Pfaller. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
12. Konishi, M., M. Nishio, K. Saltoh, T. Miyaki, T. Oki, and H. Kawaguchi. 1989. Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure. J. Antibiot. 42:1749-1755.
13. Mittendorf, J., F. Kunisch, M. Matzke, H.-C. Militzer, A. Schmidt, and W. Schoenfeld. 2003. Novel antifungal beta-amino acids: synthesis and activity against Candida albicans. Bioorg. Med. Chem. Lett. 13:433-436.
14. Morton, D. H., K. A. Strauss, D. L. Robinson, G. Puffenberger, and R. I. Kelley. 2002. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics 109:999-1008.
15. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. Ohki, H., Y. Inamoto, K. Kawabata, T. Kamimura, and K. Sakane. 1991. Synthesis and antifungal activity of FR109615 analogs. J. Antibiot. 44:546-549.
17. Oki, T., M. Hirano, K. Tomatsu, K. Numata, and H. Kamei. 1989. Cispentacin, a new antifungal antibiotic. II. In vitro and in vivo antifungal activities J. Antibiot. 42:1756-1762.
18. Pappas, P. G., J. H. Rex, J. Lee, R. J. Hamill, R. A. Larsen, W. Powderly, C. A. Kauffman, N. Hyslop, J. E. Mangino, S. Chapman, H. W. Horowitz, J. E. Edwards, W. E. Dismukes, and the NIAID Mycoses Study Group. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.
19. Perfect, J. R. 2002. New antifungal agents. Transpl. Infect. Dis. 4:52-61.
20. Petraitis, V., R. Petraitiene, A. M. Kelaher, A. A. Sarafandi, T. Sein, D. Mickiene, J. Bacher, A. H. Groll, and T. J. Walsh. 2004. Efficacy of PLD-118, a novel inhibitor of Candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. Antimicrob. Agents Chemother. 48:3959-39567.
21. Revankar, S. G., O. P. Dib, W. R. Kirkpatrick, R. K. McAtee, A. W. Fothergill, M. G. Rinaldi, S. W. Redding, and T. F. Patterson. 1998. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 26:960-963.
22. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
23. Rex, J. H., T. J. Walsh, J. D. Sobel, S. G. Filler, P. G. Pappas, W. E. Dismukes, and J. E. Edwards. 2000. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis. 30:662-678.
24. Sambrook, J., P. MacCallum, and D. W. Russell. 2000. Molecular cloning, a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
25. Sanglard, D. 2003. Clinical relevance of mechanisms of antifungal drug resistance in yeasts. Enferm. Infecc. Microbiol. Clin. 20:462-469.
26. Sanglard, D., and F. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
27. Schmidt, A., and U. Geschke. 1996. Comparative virulence of Candida albicans strains in CFW1 mice and Sprague-Dawley rats. Mycoses 39:157-160.
28. Schoenfeld, W., and M. Parnham. 2001. PLD-118, a novel antifungal for treatment of yeast infections: animal pharmacokinetics. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. 2145. American Society for Microbiology, Washington, D.C.
29. Seibold., M., and K. Tintelnot. 2003. Susceptibility testing of fungi-current status and open questions. In E. Jucker (ed.), Antifungal agents-advances and problems. Birkhauser Verlag, Basel, Switzerland.
30. Sherman, F., G. R. Fink, and C. W. Lawrence. 1979. Methods in yeast genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
31. Ziegelbauer, K. 1998. Decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance to the cyclic β-amino acid BAY 10-8888 in Candida albicans and Candida tropicalis. Antimicrob. Agents Chemother. 42:1581-1586.
32. Ziegelbauer, K., P. Babczinski, and W. Schoenfeld. 1998. Molecular mode of action of the antifungal β-amino acid BAY 10-8888. Antimicrob. Agents Chemother. 42:2197-2202.